Data to build better population health outcomes and a foundation for research
Who we are
The Health Improvement Network® (THIN®) is one of the most respected and reliable data sources for anonymised primary care records, representing approximately 6% of the UK population as far back as 1994.
Our aim is to enable advancements in patient care and outcomes by assisting healthcare authorities, academics and research organisations and leading healthcare technology companies.
THIN® is particularly concerned with the confidentiality of data, the rights of patients and Doctors. Data collated from GP Practice partners is done so in compliance with all legal and ethical frameworks.
THIN® is overseen by an independent advisory committee which includes patients, clinicians and researchers.
Population Health Management
Research that facilitates the improvement of patient care across the general population
Primary Care Policy
Use of anonymised data to help better inform Health Authorities on how primary care services can be delivered and targeted more effectively
Secondary Care Policy
Analysis of the effectiveness of referral and treatment pathways ensuring appropriate procedures are in place to enable transfer of a patient’s care across multiple healthcare settings
Understanding trends in the presence or absence of diseases and disorders and their effects on society
The assessment, monitoring and prevention of adverse effects with pharmaceutical products
Evidence for Drug Approvals
Real world data regarding the usage and potential benefits or risks of drugs
Who we help
THIN®’s database(s) are used for the purposes of patient care management, healthcare resource planning, medical research, prescribing analysis and epidemiology, benefitting the following areas of the UK healthcare landscape;
Patients - Population Health
Patients are at the core of the anonymised data collection, because the data collected at the point between doctor and patient when about symptoms, diagnosis, treatment and ongoing healthcare management is of huge value as insight. The data is collated without inclusion of any personal data making it anonymous, the data in THIN is used for research primarily to benefit future patients, to study infections, cancer, diabetes, medicine safety and many other health issues impacting future patient populations. Patients stand to gain most from what THIN delivers.
GPs and GP Practices
GPs are the primary care frontline contact between The NHS and the population. With around 6 million GP appointments every week – and almost 120 million outpatient appointments a year – in England alone, GPs are the most prolific data collectors and managers. As such we work in partnership with them to ensure the utmost quality of the information provided to THIN® and guarantee its accuracy.
Clinical Commissioning Groups and Integrated Care Systems
In their role in the Healthcare Sector and the NHS, Clinical Commissioning Groups and Integrated Care Systems and the like, play a crucial role in influencing patient journeys, treatment pathways and health outcomes. These organisations operate locally and nationally to inform decision-making in a range of crucial areas from resource planning, pathway design and medicines optimisation to disease management and drug development. Their role in public health makes them key stakeholders.
Data Users - Pharmaceutical and Academic Research Community
Research of both an academic nature and more corporate/commercial nature underpins the ability of the wider healthcare sector to develop drugs, treatments and treatment pathways for better population health. THIN® is one of the most respected and reliable data sources for anonymised primary care records, cited in over 1800 published Medical Studies worldwide. Find out why Academic Researchers, Research Teams and the Pharmaceutical industry chose THIN®.
View our latest blog posts
Cegedim Health Data expands its European database THIN® now includes German anonymized electronic health records.
Insights into the patterns of diagnosis, treatment, and outcomes of AF and other medical conditions, enabling healthcare professionals to catch comorbidities and establish effective treatments.
The University of Birmingham has partnered with Dexter and Cegedim to conduct the RADIANT trial that focuses on gestational diabetes mellitus (GDM).